Antimicrobial Resistance and Molecular Interaction with Drugs

Sridhar Alagar Ramanujan[1], Dr. Rajagopal Appavu[#] and Jothsna Kethar[#]

[1]Marriotts Ridge High School
[#]Advisor

ABSTRACT

Recently, people have been tackling a new problem in healthcare: antimicrobial resistance. Due to drug use (more specifically, drug misuse) in the previous years, bacteria have developed a resistance to modern drugs. Antimicrobial resistance makes current drugs less helpful in fighting certain types of bacteria. This study navigates on the description of antimicrobial resistance, its effects, and its solutions. Understanding Antimicrobial Resistance reveals mechanisms that microorganisms employ to render antimicrobial agents impotent. Understanding this knowledge can help make drugs more effective not only in the present but also in the future. Factors influencing antimicrobial resistance, including antibiotic misuse and horizontal gene transfer, reveal insights into the evolutionary arms race between microbes and drugs. Exploring molecular interactions between organisms and drugs can reveal the complex relationship between antimicrobial agents and pathogens. Consequences of antimicrobial resistance and strategies to combat antimicrobial resistance is another aspect that assesses the impact on patient outcomes, healthcare expenditure, and societal well-being. Approaches in drug development are from the topics of genomics, proteomics, and structural biology to increase the effectiveness of drugs. In conclusion, understanding the relationship between drugs and microorganisms lays the foundation for innovative drug development and strategies to preserve antimicrobial efficacy. Understanding this knowledge will not only help us now but will safeguard the role of drugs in the future.

Introduction

Antimicrobial resistance (AMR) has emerged as a global health crisis, challenging the efficiency of antimicrobial drugs. Understanding why this happens and ways to prevent resistance is one of the critical topics in the world today. Understanding the driving forces behind AMR begins with a glimpse into the unique properties of Antimicrobial Peptides. Unlike traditional antibiotics, which target specific bacterial structures, AMPs possess an innate ability to interact with diverse microbial targets, making the development of resistance exceedingly challenging. This investigation aims to shed light on the intricate mechanisms through which AMPs exert their antimicrobial actions, influencing the cellular landscape and bolstering the host's resilience against infections. As microorganisms adapt to fight off the exerting antimicrobial peptide, they adapt, making it even harder for antimicrobial drugs to be helpful. Misusing medications can contribute to these problems unnecessarily. Learning the molecular approach in drug development is essential to overcome antimicrobial resistance. It is also important to understand when and not to use certain drugs to preserve antimicrobial drugs in the future. This study will discuss the following topics to safeguard future drug use and overcome problems.

Understanding Antimicrobial Resistance

Antimicrobial resistance is characterized by microorganisms' ability to withstand the effects of antimicrobial drugs that were once effective in treating infections. Antimicrobial resistance, or AMR, arises through natural selection and the adaptive nature of microorganisms. As microorganisms, such as bacteria, viruses, fungi, and parasites, are exposed to antimicrobial drugs, some microorganisms tend to evolve, weakening the antimicrobial drugs. Over time, the resistance strains become dominant, which renders the previously effective medicine ineffective. The impact of antimicrobial resistance is widespread, affecting public health globally. Increasing treatment failures due to drug-resistant infections can lead to prolonged illness, higher mortality rates, and increased healthcare costs.

Moreover, AMR can result in the resurgence of once-controlled diseases. For example, once controlled by effective antimicrobial drugs, tuberculosis experienced a resurgence due to emerging and extensively drug-resistant strains. The emerging strains pose a significant challenge to preventing the effects of tuberculosis and put innocent lives at risk. Tackling the problem of AMR requires a multifaceted approach, including a more effective use of antibiotics, infection prevention, control measures, and continued research in developing new antimicrobial agents.

Antimicrobial resistance is driven by several interconnected factors on both a cellular and non-cellular level. At the non-cellular level, one significant factor is the overuse and misuse of antimicrobial drugs in human healthcare, veterinary practices, and agriculture. The overprescription of drugs and their use as growth promoters in livestock creates selective pressure that pushes microorganisms to adapt and develop resistance. In day-to-day life, inadequate infection control practices, such as poor sanitation and suboptimal hygiene practices, can foster the spread of these resistant strains. Antimicrobial-resistant strains can also travel from person to person even faster now through international trade, tourism, and interconnectedness in our global community. Another factor is environmental contamination. The release of unsafe wastewater and trash into the environment can further foster and develop resistant strains, creating a reservoir of resistant genes that can affect other organisms. Since "Bacteria and their genes move relatively easily within and between humans, animals, and the environment" (Mcewan, 2018), it is detrimental to us, the environment, and the overall ecosystem.



Figure 1. The improper disposal of contaminated wastewater and waste materials into the environment can exacerbate the development of resistant strains, effectively establishing a reservoir of genes that confer resistance. This reservoir has the potential to impact other organisms as well.

Antimicrobial resistance is caused by various mechanisms at a cellular level. Genetic mutations in microorganisms play a significant role in AMR development. As microorganisms change their DNA, there is a chance that the microorganism develops a mutation that would help it defend against the antimicrobial agents. "These mutations enable the bacteria to thrive despite antibiotic exposure, leading to treatment failures. Another mechanism that contributes to AMR is horizontal gene transfer. Horizontal gene transfer is the movement of genetic information between organisms. In this case, microorganisms can transfer genes through horizontal gene transfer, responsible for resistance against antimicrobial agents. Another mechanism that contributes to AMR is biofilm. Biofilm is a layer of mucilage that sticks to a solid surface that contains a community of bacteria and other microorganisms. Biofilm can be challenging to penetrate for antimicrobial agents, making it even harder for antibiotics. In addition, bacteria can also deploy efflux pump mechanisms to try to expel antibiotics from within the bacteria actively. Furthermore, some microorganisms produce enzymes that modify or deactivate antibiotics, rendering the antibiotics useless or not effective. Understanding these mechanisms is essential, as it is vital to combat AMR effectively.



Figure 2. Genetic mutations, horizontal gene transfers, biofilm productions, efflux pumps, enzyme inactivation, and DNA repair mechanisms are some of the ways that microorganisms can make antibiotics less effective.

Molecular Interactions between Organisms and Drugs

Antimicrobial drugs work because they interact with specific molecular targets (usually enzymes and catalysts) within the microorganisms. They interact in a way that disrupts vital processes necessary for survival. For some drugs to work, enzyme inhibition is critical. *Enzyme inhibition* is a mechanism in which drugs bind to and block the active sites for crucial enzymes, preventing the microorganism from carrying out essential biochemical reactions. Additionally, drugs can disrupt fundamental cellular processes. Some drugs target bacterial cell walls, weakening their structural integrity and causing cell lysis. For example, penicillin antibiotics interfere with the synthesis of bacterial cell walls by inhibiting the enzyme transpeptidase. This disruption weakens the bacterial cell wall, leading to cell lysis and death.

(Bush et al., 2016) Others interfere with DNA replication and protein synthesis, preventing accurate genetic replication and production. Some other antibiotics inhibit folate metabolism, which is essential for DNA and RNA synthesis. These molecular-level interactions play a crucial role in eradicating bacteria while minimizing harm to human cells.

The molecular structure of antimicrobial drugs plays a crucial role in their interaction with microorganisms. Specific structural features, such as functional groups, stereochemistry, hydrophobic and hydrophilic regions, and size and shape, are all considered to optimize the effectiveness and minimize the side effects of antimicrobial drugs. By understanding these relationships, researchers can decide whether to modify drug structures to check their effectiveness. However, as researchers modify drug structures, it is essential to consider the potential for resistance. Some resistance mechanisms involve alteration of the target site, preventing effective drug binding. Thus, understanding structure-shape relationships is critical for drug improvement and a fundamental defense against evolving resistance, requiring constant innovation to outpace microbial adaptation.

Researchers employ molecular-level techniques to modify the chemical structure of antimicrobial drugs. Researchers tailor them to counteract specific resistance mechanisms, such as altering functional groups. These modifications have successfully restored drug efficacy against otherwise resistant microbials. Ongoing research in this field is vital, as microorganisms continually adapt and new resistance mechanisms emerge, requiring the constant adaptation of drug design to counter these challenges and maintain the effectiveness of antimicrobial agents.

Consequences and Strategies to Combat Antimicrobial Resistance

Antimicrobial resistance has profound implications for healthcare systems worldwide. The rise of drug-resistant microorganisms resulted in increased morbidity and mortality among patients, as infections that were once treatable became more challenging to treat. Additionally, there is a financial cost to AMR as increased visits in a hospital mean higher hospital visits and less access to others who also need the hospital equipment. Also, healthcare professionals need help in treating patients with drug-resistant infections because there are limited treatment options, and there is a need for more expensive and toxic drugs. The spread of antimicrobial resistance within healthcare facilities is also a severe issue that risks patient and staff safety and infection control. The urgency to combat AMR has highlighted the need for better infection prevention and control measures, prudent antibiotic use, and innovative approaches to develop new antimicrobial agents.

Addressing antimicrobial resistance is a complex global challenge requiring various organizations' concentrated efforts. There has already been an international effort to tackle AMR. These efforts involve government healthcare sectors, research institutions, and non-government organizations researching and working on the issue. One of the prominent efforts is from the World Health Organization. The Global Action Plan on antimicrobial resistance aims to improve awareness, surveillance, and responsible use of antibiotics worldwide.

International organizations, such as the Center for Disease Control and the European Centre for Disease Prevention and Control, also work to monitor and control the spread of drug-resistant bacteria. Collaborative efforts among countries help facilitate the spread of drug-resistant bacteria by sharing knowledge, expertise, and resources, leading to a more unified approach to combating AMR. Furthermore, research and development collaborations are essential to effectively discover novel antimicrobial agents, diagnostics, and vaccines to fight drug-resistant bacteria.

Innovations in treatment and prevention strategies are at the forefront of the battle against antimicrobial resistance. There are multiple different ways the modern world combats AMR. Emerging therapeutic approaches are tailored to target drug-resistant bacteria, and precision medicine designed to address individual patient needs holds promise to fight off AMR. Vaccination programs are essential and play a crucial role in preventing infections caused by drug-resistant pathogens, reducing the demand for antibiotics. Alternative therapies such as bacteriocins, antimicrobial peptides, and probiotics are gaining recognition for their potential in combatting drug-resistant microorganisms. Infection control also has significant advances, including using ultraviolet light to disinfect surfaces. Concurrently, public engagement and education are paramount, as raising awareness about AMR and promoting responsible antibiotic use among the general populace are essential elements in stemming the spread of resistance. These innovations collectively reflect a multifaceted approach to tackling AMR, combining cutting-edge medical technologies with public empowerment in the global effort to preserve the effectiveness of antimicrobial drugs. At the same time, educating the public about AMRs and responsible drug use is essential. These innovations collectively reflect a multifaceted approach to tackling AMR, combining cutting-edge medical technologies with public empowerment in the global effort to preserve the effectiveness of antimicrobial drugs.

Societal and Economic Implications of Antimicrobial Resistance

Antimicrobial resistance evolves rapidly, making it a bigger and bigger issue. It is essential to look at the emerging trends and patterns in antimicrobial resistance to understand the ever-changing landscape of drug resistance. Recent studies underscore the gravity of this situation; in 2019, there were 700,000 deaths due to AMR-related infections. 2050, that amount might grow to 10,000,000 deaths due to AMR-related infections alone. (Rosini et al., 2019). These statistics are even more concerning when considering specific pathogens like methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE) have demonstrated a heightened antibiotic resistance. Additionally, certain geographical regions have witnessed the emergence of distinctive resistance profiles, with some locales experiencing significantly higher resistance rates due to factors such as antibiotic misuse and inadequate infection control. By closely examining these trends, researchers can pinpoint resistance hotspots, evaluate the efficacy of interventions, and tailor strategies to curtail the proliferation of AMR more effectively on both local and global scales. Understanding these trends is essential for shaping evidence-based public health policies and optimizing treatment approaches during this continually evolving health crisis.

Figure 3. An estimated 700,000 people died from antimicrobial resistance in 2020, which increased to a whopping 10,000,000 in 2050. That is two million people more than the population of New York City. That number will continue to grow if the world does not combat antimicrobial resistance.

Antimicrobial resistance significantly burdens society physically and economically. First, the consequences of AMR are seen throughout healthcare systems, leading to increased morbidity, mortality, and exorbitant healthcare costs. Economic implications include the strain on healthcare systems, decreased efficiency, and potential threats to food security, altogether putting substantial economic burdens on nations. Studies have shown that antibiotic resistance can cost up to $1400 of extra expenses per patient alone. (Dagostar 2019) For the United States economy, it could cost an estimated 300 billion dollars to treat antimicrobial resistance by 2050. (Dagostar 2019) In response to this growing crisis, global initiatives and collaborative efforts have emerged as vital components of the battle against AMR.

Molecular Approaches in Drug Development and Overcoming Resistance

Drugs interact with target molecules at a molecular level through specific interactions such as hydrogen bonding, electrostatic, and hydrophobic interactions. These interactions enable drugs to bind to their target proteins or enzymes, altering their activity and inhibiting vital cellular processes. This drug design development process involves several stages:

1. Target identification: Researchers identify vital molecules or pathways in the microorganism that can be targeted for therapeutic intervention.
2. Lead compounds are discovered through various methods, such as high-throughput screening or computer-aided-drug design. These lead compounds are further optimized through structural modifications to improve potency, selectivity, and pharmacokinetic properties.
3. Pre-clinical testing is done to see the safety and efficacy of these newly designed products before potential clinical use.

One of the ways researchers have tried to overcome resistance is combination therapy. Combination therapy involves multiple drugs with different mechanisms of action that target microorganisms simultaneously. This approach aims to prevent the emergence of resistance by attacking the microorganism through different pathways, making it harder for resistance to develop. Combination therapy has proven effective in treating drug-resistant bacteria. For example, in tuberculosis, combination therapy with multiple antibiotics targets different stages of the TB life cycle, preventing the development of drug-resistant bacteria. In addition to combination therapies, innovative approaches are being explored to combat antimicrobial resistance. Drug repurposing involves finding new uses for existing drugs that may have antimicrobial properties, providing potential alternatives to traditional antibiotics. Nanotechnology offers promising applications in drug delivery, enabling targeted and controlled release of antimicrobial drug delivery to improve efficacy while minimizing side effects. Adjuvants are compounds that enhance the effectiveness of antimicrobial drugs and are being investigated to improve treatment outcomes and reduce the development of resistance.

Research efforts are focused on understanding the intricate mechanisms of antimicrobial resistance to devise effective strategies against it. One notable example is whole genome sequencing. Whole genome sequencing allows researchers to analyze the complete genetic makeup of microorganisms, identifying specific genetic mutations that confer resistance. Another notable example is CRISPR-CAS9 technology, which revolutionizes gene editing, enabling precise modifications to study resistance-related genes and validate their roles in drug resistance. Metagenomics is a powerful approach to exploring resistomes (an inherited set of genes used to resist infections). Metagenomics has revealed the diversity and the distribution of resistance genes within microbial communities. Additionally, single-cell analysis provides insights into the dynamics of resistance development in heterogeneous microbial populations. These advances, with previous advances in biology, are essential in designing targeted therapies, identifying novel drug targets, and developing effective strategies to combat antimicrobial resistance and preserve the efficacy of existing antimicrobial agents.

Conclusion

Antimicrobial resistance poses a significant threat to global health, requiring a multifaceted and collaborative approach to address its challenges effectively. Understanding the molecular interactions between microorganisms and drugs is crucial in designing efficient antimicrobial agents. Combination therapies and innovative techniques have shown promise in overcoming resistance to diseases like HIV and tuberculosis, while global initiatives and collaborative efforts enhance awareness, surveillance, and responsible antimicrobial use. Advances in understanding resistance mechanisms, helped by technologies like genome sequencing and CRISPR-Cas9, provide valuable insight for developing targeted therapies. By uniting these efforts, combating AMR becomes easier to tackle and can preserve the effectiveness of antimicrobial agents and secure a healthier future for humanity.

Acknowledgments

I want to thank Coach Jo from Gifted Gabber for guiding me. I also want to thank Dr. Rajagopal for helping me with my research by giving me new pathways of knowledge.

References

Baquero, F., Martínez, J. L., Lanza, V. F., Rodríguez-Beltrán, J., Galán, J. C., Millan, A. S., Cantón, R., & Coque, T. M. (2021). Evolutionary pathways and trajectories in antibiotic resistance. *Clinical Microbiology Reviews*, *34*(4). https://doi.org/10.1128/cmr.00050-19

Brinkac, L., Voorhies, A. A., Gomez, A., & Nelson, K. E. (2017). The threat of antimicrobial resistance on the human microbiome. *Microbial Ecology*, *74*(4), 1001–1008. https://doi.org/10.1007/s00248-017-0985-z

Bush, K., & Bradford, P. A. (2016). B-Lactams and B-Lactamase inhibitors: an overview. *Cold Spring Harbor Perspectives in Medicine*, *6*(8), a025247. https://doi.org/10.1101/cshperspect.a025247

Cunha, C. B. (2018). Antimicrobial stewardship programs. *Medical Clinics of North America*, *102*(5), 797–803. https://doi.org/10.1016/j.mcna.2018.04.003

Dadgostar, P. (2019). <p>Antimicrobial Resistance: Implications and Costs</p> *Infection and Drug Resistance*, *Volume 12*, 3903–3910. https://doi.org/10.2147/idr.s234610

Kok, M., Maton, L., Van Der Peet, M., Hankemeier, T., & Van Hasselt, J. G. C. (2022). Unraveling antimicrobial resistance using metabolomics. *Drug Discovery Today*, *27*(6), 1774–1783. https://doi.org/10.1016/j.drudis.2022.03.015

McEwen, S. A., & Collignon, P. (2018). Antimicrobial Resistance: a One Health Perspective. *Microbiology Spectrum*, *6*(2). https://doi.org/10.1128/microbiolspec.arba-0009-2017

Mesa-Varona, O., Chaintarli, K., Muller-Pebody, B., Anjum, M. F., Eckmanns, T., Norström, M., Boone, I., & Tenhagen, B. (2020). "Monitoring Antimicrobial Resistance and Drug Usage in the Human and Livestock Sector and Foodborne Antimicrobial Resistance in Six European Countries" *Infection and Drug Resistance*, *Volume 13*, 957–993. https://doi.org/10.2147/idr.s237038

Munita, J. M., & Arias, C. A. (2016). Mechanisms of antibiotic resistance. *Microbiology Spectrum*, *4*(2). https://doi.org/10.1128/microbiolspec.vmbf-0016-2015

Penicillin's discovery and antibiotic resistance: lessons for the future? (2017, March 29). PubMed. https://pubmed.ncbi.nlm.nih.gov/28356901/

Rosini, R., Nicchi, S., Pizza, M., & Rappuoli, R. (2020). Vaccines against antimicrobial resistance. *Frontiers in Immunology*, *11*. https://doi.org/10.3389/fimmu.2020.01048

Talaat, M., Zayed, B., Tolba, S., Abdou, E., Gomaa, M., Itani, D., Hutin, Y., & Hajjeh, R. (2022). Increasing antimicrobial resistance in World Health Organization Eastern Mediterranean Region, 2017–2019. *Emerging Infectious Diseases*, *28*(4). https://doi.org/10.3201/eid2804.211975

What Exactly is Antibiotic Resistance? (2022, October 5). Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/about.html

What Exactly is Antibiotic Resistance? (2022, October 5). Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/about.html

World Health Organization: WHO. (2021). Antimicrobial resistance. *www.who.int*. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance